MYUNGMOON Pharm co.,Ltd (KRX:017180)
South Korea · Delayed Price · Currency is KRW 1,807.00
+3.00 (0.17%)
Apr 8, 2026, 3:30 PM KST
MYUNGMOON Pharm co.,Ltd Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 195,247 | 186,443 | 169,567 | 152,135 | 137,760 |
Other Revenue | -0 | - | -0 | -0 | -0 |
| 195,247 | 186,443 | 169,567 | 152,135 | 137,760 | |
Revenue Growth (YoY) | 4.72% | 9.95% | 11.46% | 10.44% | 7.75% |
Cost of Revenue | 88,861 | 81,949 | 74,658 | 74,528 | 75,965 |
Gross Profit | 106,386 | 104,494 | 94,909 | 77,607 | 61,795 |
Selling, General & Admin | 97,316 | 100,698 | 90,417 | 66,846 | 66,213 |
Research & Development | 3,985 | 2,059 | 2,970 | 1,711 | 2,065 |
Amortization of Goodwill & Intangibles | 21.52 | 9.81 | 58.6 | 70.52 | 68.3 |
Other Operating Expenses | 1,501 | 1,344 | 1,358 | 1,365 | 1,506 |
Operating Expenses | 99,552 | 102,565 | 93,946 | 71,173 | 67,675 |
Operating Income | 6,835 | 1,929 | 963.77 | 6,434 | -5,881 |
Interest Expense | -5,090 | -5,352 | -5,137 | -3,735 | -3,042 |
Interest & Investment Income | 37.61 | 109.68 | 225.05 | 152.17 | 199.05 |
Currency Exchange Gain (Loss) | 14.93 | 45.93 | 46 | -0.77 | 17.34 |
Other Non Operating Income (Expenses) | 797.16 | 826.22 | -132.13 | -275.32 | 1,163 |
EBT Excluding Unusual Items | 2,595 | -2,441 | -4,035 | 2,575 | -7,543 |
Gain (Loss) on Sale of Investments | 30.27 | 63.24 | -36.24 | 95.02 | 498.6 |
Gain (Loss) on Sale of Assets | 22.85 | -512.21 | 25.61 | -14.03 | 895.37 |
Asset Writedown | - | -854.35 | -736.22 | -4.2 | -448.76 |
Pretax Income | 2,648 | -3,744 | -4,782 | 2,652 | -6,598 |
Income Tax Expense | 1,230 | 45.4 | 92.61 | -5,324 | 206.14 |
Earnings From Continuing Operations | 1,418 | -3,790 | -4,874 | 7,976 | -6,804 |
Minority Interest in Earnings | 477.5 | 755.39 | 349.41 | -108.07 | -60.25 |
Net Income | 1,895 | -3,035 | -4,525 | 7,868 | -6,865 |
Net Income to Common | 1,895 | -3,035 | -4,525 | 7,868 | -6,865 |
Shares Outstanding (Basic) | 33 | 33 | 34 | 34 | 34 |
Shares Outstanding (Diluted) | 33 | 33 | 34 | 34 | 34 |
Shares Change (YoY) | -0.29% | -0.99% | -0.38% | - | 15.48% |
EPS (Basic) | 57.00 | -91.00 | -134.35 | 232.74 | -203.06 |
EPS (Diluted) | 57.00 | -91.00 | -134.35 | 232.74 | -203.06 |
Free Cash Flow | -8,462 | -2,109 | -8,164 | 3,744 | 480.28 |
Free Cash Flow Per Share | -254.50 | -63.25 | -242.39 | 110.75 | 14.21 |
Gross Margin | 54.49% | 56.05% | 55.97% | 51.01% | 44.86% |
Operating Margin | 3.50% | 1.03% | 0.57% | 4.23% | -4.27% |
Profit Margin | 0.97% | -1.63% | -2.67% | 5.17% | -4.98% |
Free Cash Flow Margin | -4.33% | -1.13% | -4.81% | 2.46% | 0.35% |
EBITDA | 10,796 | 5,994 | 5,132 | 10,672 | -1,678 |
EBITDA Margin | 5.53% | 3.21% | 3.03% | 7.02% | -1.22% |
D&A For EBITDA | 3,962 | 4,066 | 4,168 | 4,238 | 4,203 |
EBIT | 6,835 | 1,929 | 963.77 | 6,434 | -5,881 |
EBIT Margin | 3.50% | 1.03% | 0.57% | 4.23% | -4.27% |
Effective Tax Rate | 46.45% | - | - | - | - |
Advertising Expenses | 1,317 | 1,348 | 1,372 | 1,314 | 993.55 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.